Systematic Review of Genomic-Based Risk Stratification in Localised Prostate Cancer Treatment Optimisation: Clinical Impact and Health Economic Evidence - PubMed
3 days ago
- #health economics
- #genomic risk stratification
- #prostate cancer
- Genomic risk stratification tests help predict metastasis and mortality in prostate cancer patients at diagnosis.
- The review evaluates clinical impact and cost-effectiveness of four genomic tests: Oncotype DX Prostate Score, ProMark, Prolaris, and Decipher Genomic Classifier.
- Most studies showed genomic tests reclassified patients into lower- and higher-risk groups, influencing treatment decisions between active surveillance and radical treatment.
- Prognostic value was validated for biopsy upgrade, metastasis, and death.
- Oncotype DX Prostate Score and ProMark were found cost-effective; Prolaris was cost-saving in the US but not in Canada.
- Limited long-term clinical and health economic evidence calls for further research to assess cost-effectiveness in clinical practice.